Buch, Englisch, 151 Seiten, Format (B × H): 155 mm x 235 mm, Gewicht: 260 g
Reihe: Milestones in Drug Therapy
Buch, Englisch, 151 Seiten, Format (B × H): 155 mm x 235 mm, Gewicht: 260 g
Reihe: Milestones in Drug Therapy
ISBN: 978-3-0348-9451-7
Verlag: Birkhäuser Basel
HMG-CoA reductase inhibitors (statins) are established drugs for the
treatment of hypercholesterolemia. Furthermore, they induce regression
of vascular atherosclerosis as well as reduction of
cardiovascular-related morbidity and death in patients with and without
coronary artery disease. This book deals with statins which have
substantially altered the approach to therapy of atherosclerosis and its
sequelae. Emphasis is placed on the scientific background to the
discoveries and the development of the therapy, including an overview of
the current state of knowledge of the drugs. Clinical data are reviewed
extensively. This book not only provides the reader with valuable
information but also stimulates further research into the pathogenesis
of atherosclerosis and the mechanisms behind the action of effective
statins. It sets the stage for creative thinking among scientists of
many disciplines for the accomplishment of our ultimate goals in
treating atherosclerosis and its sequelae. This topical volume.
Zielgruppe
Research
Autoren/Hrsg.
Weitere Infos & Material
History and development of HMG-CoA reductase inhibitors.- Structure and mechanisms of action of HMG-CoA reductase inhibitors.- Sterol-regulatory element binding proteins (SREBPs): gene-regulatory target of statin action.- Cellular effects of HMG-CoA reductase inhibitors on blood cells (monocytes, macrophages, platelets).- Pleiotropic effects of HMG-CoA reductase inhibitors on cells of the vascular wall.- Indications and contra-indications for statin treatment (primary and secondary prevention of hypercholesterolemia).- Clinical experience: studies with HMG-CoA reductase inhibitors.- Cost-effectiveness of statins in primary and secondary prevention of coronary heart disease.
